LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

11.64 -2.51

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.22

Max

11.84

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.506 49.701
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+66.81% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.1B
Ankstesnė atidarymo kaina	14.15
Ankstesnė uždarymo kaina	11.64

Naujienos nuotaikos

By Acuity

10%

90%

8 / 345 reitingas Healthcare

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-25 08:24; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026-05-25 21:22; UTC

Uždarbis

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026-05-25 20:50; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:20; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:01; UTC

Rinkos pokalbiai

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026-05-25 14:43; UTC

Rinkos pokalbiai

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026-05-25 14:15; UTC

Rinkos pokalbiai

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026-05-25 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-25 12:58; UTC

Rinkos pokalbiai

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026-05-25 12:56; UTC

Rinkos pokalbiai

Uždarbis

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-25 12:34; UTC

Rinkos pokalbiai

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026-05-25 12:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero's Assets Look Strategic -- Market Talk

2026-05-25 11:00; UTC

Rinkos pokalbiai

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026-05-25 10:19; UTC

Rinkos pokalbiai

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026-05-25 10:05; UTC

Uždarbis

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026-05-25 10:04; UTC

Uždarbis

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026-05-25 10:03; UTC

Uždarbis

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026-05-25 10:02; UTC

Uždarbis

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026-05-25 10:01; UTC

Uždarbis

Tenaga Nasional 1Q Net Up 3.7% on Year

2026-05-25 10:00; UTC

Uždarbis

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q EPS MYR0.1883

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Rev MYR17.1B

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Net MYR1.1B

2026-05-25 09:38; UTC

Rinkos pokalbiai

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026-05-25 08:55; UTC

Rinkos pokalbiai

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

66.81% į viršų

12 mėnesių prognozė

Vidutinis 20 USD 66.81%

Aukščiausias 20 USD

Žemiausias 20 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

8 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.